Metabolic Syndrome and the Risk of Depression and Anxiety: A Prospective Cohort Study

Q: What are the key findings of this study?

Metabolic syndrome was significantly associated with increased risks of incident depression (HR 1.27, 95% CI 1.22–1.32) and anxiety (HR 1.17, 95% CI 1.12–1.21) over 14.07 years of follow-up.

Q: What is the clinical evidence from this study?

Study design: Cohort. Population: Metabolic syndrome and risk of incident depression and anxiety (n=316263). Intervention: Metabolic syndrome (NCEP ATP III criteria) vs. No metabolic syndrome. Primary outcome: Incident depression (HR 1.27, 95% CI 1.22–1.32, p=<0.001).

Q: What does this research mean for the field?

Metabolic syndrome increases the risk of incident depression and anxiety in a dose-response manner, an association driven largely by central obesity and low HDL-C and partially mediated by systemic inflammatory markers. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Q: What question did this study set out to answer?

To prospectively investigate whether metabolic syndrome and its individual components increase the risk of developing new-onset depressive and anxiety disorders.

Siyi Shen; Xinmeng Yao; Qixin Zhang; Ziyi Huang; Jiayu Li; Fei Pan; Yingying Mao; Xian Zhang

doi:10.21203/rs.3.rs-11111280/v1

October 11, 2026Open Access

Metabolic Syndrome and the Risk of Depression and Anxiety: A Prospective Cohort Study

View Full Paper

Ask AI

Bookmark

Share

Key result

Metabolic syndrome is linked to ~27% higher risk of incident depression.

HR 1.27
95% CI 1.22–1.32
P<0.001
n=316,263

Why the study?

The relationship between metabolic syndrome (MetS) and the risk of incident depressive and anxiety disorders remained unclear.

Does metabolic syndrome increase the risk of incident depression and anxiety disorders in middle-aged and older adults?

Key Points

To prospectively investigate whether metabolic syndrome and its individual components increase the risk of developing new-onset depressive and anxiety disorders.
Prospective cohort study of 316,263 participants followed for a median of 14.07 years, with metabolic syndrome defined using NCEP ATP III criteria.
Multivariable Cox regression models and restricted cubic splines evaluated risk estimates, component combinations, and dose-response associations.
Mediation analyses assessed the potential mediating role of nine circulating inflammatory markers, including leukocyte and neutrophil counts.
Metabolic syndrome was associated with significantly increased risks of depression (HR 1.27, 95% CI 1.22–1.32) and anxiety (HR 1.17, 95% CI 1.12–1.21), exhibiting clear dose-response patterns (all P trend < 0.001).
Among individual components, reduced HDL-C exhibited the strongest association with depression (HR 1.31, 95% CI 1.26–1.36) and anxiety (HR 1.20, 95% CI 1.15–1.24), while combining elevated waist circumference with reduced HDL-C presented the highest joint risk.
Mediation analyses showed that leukocyte and neutrophil counts explained 7.0% of the metabolic syndrome–depression association and 12.0% to 14.0% of the metabolic syndrome–anxiety association.

Study Design

Type

Cohort (n=316,263)

Multicenter

Yes

Structured PICO

Does metabolic syndrome increase the risk of incident depression and anxiety disorders in middle-aged and older adults?

P

Population

316,263 UK Biobank participants aged 37-73 years (52.48% female, median age 58 years) free of baseline depression or anxiety, followed for a median of 14.07 years.

E

Exposure

Exposure: Metabolic syndrome (MetS) defined according to NCEP ATP III guidelines (presence of ≥3 of 5 components: increased waist circumference, elevated triglycerides, decreased HDL-C, elevated blood pressure, or hyperglycemia defined as HbA1c ≥42.0 mmol/mol or taking glucose-lowering medications), as well as cumulative MetS component scores (0 to 5), individual components, and component combinations.

C

Comparator

Participants without metabolic syndrome (<3 MetS components, n=210,394) or with 0 MetS components (n=48,895).

O

Outcome

Incident depression (ICD-10 codes F32 and F33) and incident anxiety (ICD-10 codes F40 and F41) identified through UK Biobank 'First Occurrences' records (integrating primary care, hospital inpatient, death registries, and self-reported conditions) over a median follow-up of 14.07 years (until May 1, 2023).hard clinical

Main Result

Hazard Ratio: 1.27 (95% CI 1.22–1.32)

Absolute Event Rate: 5.4% vs 3.8%

p-value: p=<0.001

Metabolic syndrome—especially the phenotype of central obesity and reduced HDL-C—independently increases the risk of incident depression and anxiety in a dose-dependent manner, partially mediated by systemic low-grade inflammation.

Limitations

Metabolic syndrome and its components were assessed only at a single baseline measurement, failing to capture longitudinal changes over time.
Residual confounding cannot be completely ruled out despite multivariable adjustments.
Participants were predominantly of European descent (95.27% White) with relatively high socioeconomic status, limiting generalizability to other populations.
Limited sample size of subjects with available fasting blood glucose levels in the UK Biobank required adopting HbA1c as an alternative biomarker for hyperglycemia

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Supports monitoring for depression/anxiety in metabolic syndrome; leaves open causality and need for intervention trials.

Abstract

Background : The relationship between metabolic syndrome (MetS) and incident depression and anxiety remains unclear. This study prospectively examined whether MetS increases the risk of new-onset depressive and anxiety disorders. Methods : This prospective cohort study included 316,263 participants from a large population-based cohort, with MetS defined according to NCEP ATP III guidelines. Multivariable Cox regression models estimated the association of MetS and its five components with outcomes. Restricted cubic splines were applied to explore dose-response relationships, and mediation analyses assessed the potential role of nine inflammatory markers. Results : Over a median follow-up of 14.07 years, 13,714 depression and 13,903 anxiety incident cases were identified. MetS was associated with increased risks of depression (HR 1.27, 95% CI 1.22–1.32) and anxiety (HR 1.17, 95% CI 1.12–1.21), with clear dose-response relationships (all P trend < 0.001). Further RCS analysis revealed a J-shaped association between SBP and depression. Among individual components, reduced HDL-C showed the strongest positive association with depression (HR 1.31, 95% CI 1.26–1.36) and anxiety (HR 1.20, 95% CI 1.15–1.24). The combination of elevated WC and reduced HDL-C demonstrated the highest risk for depression (HR 1.30, 95% CI 1.24–1.36) and anxiety (HR 1.20, 95% CI 1.14–1.26). Mediation analyses indicated that leukocyte and neutrophil counts explained 7.0% of the MetS-depression association and 12.0–14.0% of the MetS-anxiety association. Subgroup analyses revealed stronger associations in participants aged under 58 years and those with higher education. Conclusions : Our findings suggest that MetS, particularly the phenotype characterized by central obesity and dyslipidemia, may serve as a modifiable risk marker for depression and anxiety. The partial mediation by inflammatory markers supports the role of systemic low-grade inflammation in linking metabolic dysfunction to mental disorders, highlighting the potential value of integrating metabolic and inflammatory screening into mental health risk assessment.

Cite This Study

Shen et al. (2026) conducted a cohort in Metabolic syndrome and risk of incident depression and anxiety (n=316,263). Metabolic syndrome (NCEP ATP III criteria) vs. No metabolic syndrome was evaluated on Incident depression (HR 1.27, 95% CI 1.22–1.32, p=<0.001). Metabolic syndrome was significantly associated with increased risks of incident depression (HR 1.27, 95% CI 1.22–1.32) and anxiety (HR 1.17, 95% CI 1.12–1.21) over 14.07 years of follow-up.

synapsesocial.com/papers/6ae682a3e432e7a5c4ef35e1 https://doi.org/10.21203/rs.3.rs-11111280/v1

View Full Paper

Ask AI

Bookmark

Share

Metabolic Syndrome and the Risk of Depression and Anxiety: A Prospective Cohort Study

Key Points

Study Design

Structured PICO

Main Result

Limitations

Discussion

Implication

Abstract

Cite This Study

Metabolic Syndrome and the Risk of Depression and Anxiety: A Prospective Cohort Study

Key Points

Study Design

Structured PICO

Main Result

Limitations

Discussion

Implication

Abstract

Cite This Study

Keep reading

Keep reading